Biotechnological applications from a Leishmania amastigote-specific hypothetical protein in the canine and human visceral leishmaniasis

Oliveira‐da‐Silva, João A.; Machado, Amanda S.; Tavares, Grasiele S.V.; Ramos, Fernanda F.; Lage, Daniela P.; Ludolf, Fernanda; Steiner, Bethina T.; Reis, Thiago A.R.; Santos, Thaís T.O.; Costa, Lourena E.; Bandeira, Raquel S.; Martins, Vívian T.; Galvani, Nathália Coral; Chaves, Ana Cristina; Oliveira, Jamil S.; Chávez-Fumagalli, Miguel Á.; Tupinambás, Unaí; Magalhães-Soares, Danielle F. de; Silveira, Júlia A.G.; Lyon, Sandra; Machado-de-Ávila, Ricardo Andrez; Coelho, Eduardo Antônio Ferraz

doi:10.1016/j.micpath.2020.104283

Cited by 6 publications

(10 citation statements)

References 59 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[ 82 ], in which the cases were selected from a health service or hospital. To assess the performance of peptide-based tests, three different formats were reported: one study used an ICT format [ 7 ], two studies used phage-ELISA [ 15 , 62 ] and 19 studies used an ELISA technique [ 10 , 11 , 16 , 17 , 26 , 27 , 29 , 35 , 37 , 40 – 43 , 47 , 48 , 58 , 63 , 69 , 70 ]. In these studies using an ELISA method, a marked difference was observed in the amount of peptides used, which ranged from 0.25 μg to 20 μg per well.…”

Section: Resultsmentioning

confidence: 99%

“…et al ., 2020a [ 47 ] Peptide Molecular technique ELISA 2 μg/well II VL Brazil L. infantum Oliveira-da-silva, J.A. et al ., 2020b [ 48 ] PeptJ Molecular technique (VL patients); serology (control group) ELISA 2 μg/well II VL Brazil L. infantum Ramos F.F. et al ., 2021 [ 58 ] Pep1 Molecular technique (VL and VL/HIV-coinfeted patients), serological test (Kalazar detect Rapid test kit) (control group) ELISA 2.5 μg/well II VL Brazil L. infantum Pep2 5 μg/well Pep3 5 μg/well Pep4 2.5 μg/well Pep5 1.25 μg/well Pep6 1.25 μg/well Pep7 1.25 μg/well Pep8 2.5 μg/well Pep9 1.25 μg/well ...…”

Section: Resultsmentioning

confidence: 99%

“…et al ., 2020a [ 47 ] AIREAKQKDHDHSDPTPDKATGSTK Peptide Pyridoxal kinase PK LINJ_30_1310 Oliveira-da-silva, J.A. et al ., 2020b [ 48 ] EGVQEEDPTSLKNLFV PeptJ Hypothetical protein LiHyJ XP_001462647.1 Ramos F.F. et al ., 2021 [ 58 ] TSKFWDT Pep1 Trypoanothione reductase and Tyrosine aminotransferase 2JK6_A and 4IX8_A HITANES Pep2 LRINNQS Pep3 Trypoanothione reductase 2JK6_A TTHTYFG Pep4 Trypoanothione reductase and Glyoxalase II 2JK6_A and 2P18_A PAPSRMV Pep5 Glyoxalase II 2P18_A DPSPWRQ Pep6 Tyrosine aminotransferase 4IX8_A HRYSPSF Pep7 Trypoanothione reductase 2JK6_A DPTTQYS Pep8 ND ND SNYHSRW Pep9 …”

Section: Resultsmentioning

confidence: 99%

“…Sample size ranged from 27 to 210 patients ( Supplementary data 2 ). Ten publications assessed VL diagnosis with cases from Brazil (nine studies) [ 11 , 16 , 17 , 37 , 47 , 48 , 58 , 62 , 69 ] and from Sudan (one study) [ 7 ]. Four publications assessed TL (CL and ML) diagnosis with cases from Brazil (three studies) [ 15 , 40 , 63 ], and from Peru (one study) [ 29 ].…”

Section: Resultsmentioning

confidence: 99%

See 3 more Smart Citations

A systematic review of peptide-based serological tests for the diagnosis of leishmaniasis

et al. 2023

View full text Add to dashboard Cite

Serological methods should meet the needs of leishmaniasis diagnosis due to their high sensitivity and specificity, economical and adaptable rapid diagnostic test format, and ease of use. Currently, the performances of serological diagnostic tests, despite improvements with recombinant proteins, vary greatly depending on the clinical form of leishmaniasis and the endemic area. Peptide-based serological tests are promising as they could compensate for antigenic variability and improve performance, independently of Leishmania species and subspecies circulating in the endemic areas. The objective of this systematic review was to inventory all studies published from 2002 to 2022 that evaluate synthetic peptides for serological diagnosis of human leishmaniases and also to highlight the performance (e.g., sensitivity and specificity) of each peptide reported in these studies. All clinical forms of leishmaniasis, visceral and tegumentary, and all Leishmania species responsible for these diseases were considered. Following PRISMA statement recommendations, 1,405 studies were identified but only 22 articles met the selection criteria and were included in this systematic review. These original research articles described 77 different peptides, of which several have promising performance for visceral or tegumentary leishmaniasis diagnosis. This review highlights the importance of and growing interest in synthetic peptides used for serological diagnosis of leishmaniases, and their performances compared to some widely used tests with recombinant proteins.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

See 2 more Smart Citations

A systematic review of peptide-based serological tests for the diagnosis of leishmaniasis

et al. 2023

View full text Add to dashboard Cite

show abstract

“…LiHyQ was evaluated for its ability to diagnose TL, HVL and CanVL and showed a superior diagnostic performance compared with a parasite antigenic preparation and two commercial kits ( 73 ). Additionally, LiHyJ showed high sensitivity and specificity values in diagnosing HVL and canVL ( 74 ). Furthermore, rGTP protein was recently shown to be protective against experimental VL in a murine model ( 76 ).…”

Section: Immunoproteomics For Visceral Leishmaniasismentioning

confidence: 99%

Immunoproteomics and phage display in the context of leishmaniasis complexity

2023

Self Cite

View full text Add to dashboard Cite

Leishmaniasis is defined as a complex of diseases caused by protozoan parasites of the genus Leishmania, which comprises 20 parasite species pathogenic to mammalians, such as humans and dogs. From a clinical point of view, and considering the diversity and biological complexity of the parasites, vectors, and vertebrate hosts, leishmaniasis is classified according to the distinct clinical manifestations, such as tegumentary (involving the cutaneous, mucosal, and cutaneous-diffuse forms) and visceral leishmaniasis. Many issues and challenges remain unaddressed, which could be attributed to the complexity and diversity of the disease. The current demand for the identification of new Leishmania antigenic targets for the development of multicomponent-based vaccines, as well as for the production of specific diagnostic tests, is evident. In recent years, biotechnological tools have allowed the identification of several Leishmania biomarkers that might potentially be used for diagnosis and have an application in vaccine development. In this Mini Review, we discuss the different aspects of this complex disease that have been addressed by technologies such as immunoproteomics and phage display. It is extremely important to be aware of the potential applications of antigens selected in different screening context, so that they can be used appropriately, so understanding their performance, characteristics, and self-limitations.

show abstract

Immunization with recombinant LiHyp1 protein plus adjuvant is protective against tegumentary leishmaniasis

Jesus,

Lage,

Vale

et al. 2023

Parasitol Res

View full text Add to dashboard Cite

Biotechnological applications from a Leishmania amastigote-specific hypothetical protein in the canine and human visceral leishmaniasis

Cited by 6 publications

References 59 publications

A systematic review of peptide-based serological tests for the diagnosis of leishmaniasis

A systematic review of peptide-based serological tests for the diagnosis of leishmaniasis

Immunoproteomics and phage display in the context of leishmaniasis complexity

Immunization with recombinant LiHyp1 protein plus adjuvant is protective against tegumentary leishmaniasis

Contact Info

Product

Resources

About